Lite Strategy (NASDAQ:LITS) Upgraded by Wall Street Zen to “Hold” Rating

Lite Strategy (NASDAQ:LITS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Friday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lite Strategy in a research note on Saturday, September 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Lite Strategy Stock Down 4.5%

LITS opened at $2.56 on Friday. The company has a market cap of $91.26 million, a price-to-earnings ratio of -0.54 and a beta of 0.36. Lite Strategy has a 52 week low of $1.46 and a 52 week high of $9.00.

Lite Strategy Company Profile

MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.